Insurance GLP-1 shots
From W8MD weight loss and sleep centers
Detailed guide to insurance coverage, prior authorization, denials, appeals, and affordable self-pay options for GLP-1 weight loss shots through W8MD
Semaglutide from $29.99/week and up* Tirzepatide from $45/week and up*
Brooklyn: (718) 946-5500 Philadelphia: (215) 676-2334 Request an appointment
For qualifying medical visits
When medication coverage is available
Often possible when the plan permits
For exclusions, denials, or nonqualification
Insurance GLP-1 shots refers to prescription GLP-1 weight loss injections and related incretin medications obtained through a patient's health-insurance or pharmacy benefit. Examples may include Wegovy, Zepbound, Saxenda, Wegovy tablets, or Foundayo, depending on the plan's formulary and the patient's eligibility.
W8MD Weight Loss, Sleep and MedSpa accepts many insurance plans for qualifying medical weight-loss visits at its offices in Brooklyn, New York, and Philadelphia, Pennsylvania.
When a patient's insurance policy includes coverage for GLP-1 weight-loss medication and the patient qualifies under the plan's body mass index, comorbidity, and other clinical requirements, W8MD can document medical necessity and help obtain a GLP-1 prior authorization.
W8MD can also often submit prior-authorization requests when W8MD does not participate in the patient's medical insurance network, provided that:
- The pharmacy benefit permits prescriptions from an out-of-network provider;
- The insurance company accepts prior-authorization requests from that provider;
- The patient has appropriate pharmacy coverage;
- The requested medication is a covered benefit; and
- The patient satisfies the plan's medical criteria.
Important distinction: W8MD's network participation for an office visit is separate from whether the patient's pharmacy benefit covers Wegovy, Zepbound, or another GLP-1 medication. A patient may have an out-of-network medical visit but still have medication coverage through a separate pharmacy benefit. Conversely, a plan may cover the W8MD visit but exclude weight-loss medications.
Coverage • Medical versus pharmacy benefits • Prior authorization • Out-of-network requests • Eligibility • Required documentation • Denials • Appeals • Affordable options • Pricing • FAQ • Appointments
Does insurance cover GLP-1 weight loss shots?
Insurance coverage varies widely. Some policies provide extensive coverage for anti-obesity treatment, while others completely exclude medications used for weight management.
Coverage may depend on:
- The patient's insurance company
- The specific plan selected by the employer or member
- Whether obesity medication is included in the pharmacy benefit
- The requested medication
- The medication's FDA-approved indication
- The patient's diagnosis
- Current body mass index
- Previous BMI and weight history
- Weight-related comorbid conditions
- Previous weight-management attempts
- Previous medications
- Step-therapy requirements
- Participation in a structured weight-management program
- Whether the prescriber can submit through the plan's authorization system
- Whether the prescription is filled at an in-network pharmacy
- The patient's deductible, copay, or coinsurance
- Employer or government-program exclusions
- Renewal requirements
Coverage may also change during the year because of formulary changes, employer benefit decisions, regulatory changes, or updates to the insurer's medical criteria.
Three separate insurance questions
Patients often ask, “Do you accept my insurance?” That question can refer to three different benefits.
1. Is W8MD in network for the medical visit?
This determines how the physician-supervised weight-loss consultation and follow-up visits may be processed.
An in-network visit may be subject to:
- A specialist or primary-care copay
- Coinsurance
- A deductible
- Referral requirements
- Limits on nutrition or obesity-related services
- Medical-necessity rules
An out-of-network visit may be:
- Covered under out-of-network benefits;
- Applied to an out-of-network deductible;
- Reimbursable after submission of a claim;
- Subject to a higher coinsurance; or
- Not covered by the medical plan.
W8MD accepts many insurance plans for qualifying visits. Patients should verify participation, referral requirements, copays, deductibles, and out-of-network benefits directly with their plan.
2. Does the pharmacy benefit cover GLP-1 weight-loss medication?
Prescription benefits are frequently administered separately from medical benefits. Pharmacy coverage determines whether medications such as Wegovy or Zepbound are included on the formulary.
A patient's pharmacy benefit may be administered by:
- The health insurer
- A pharmacy-benefit manager
- A Medicare Part D plan
- Medicaid or a managed-care organization
- An employer pharmacy plan
- A union or government employee plan
- Another prescription-benefit administrator
The pharmacy benefit may cover the medication even when W8MD is out of network for medical visits, provided the plan accepts prescriptions and authorization requests from the W8MD provider.
3. Does the patient meet the prior-authorization criteria?
Even when a medication appears on the formulary, payment is not automatic. The plan may require proof that the patient meets its medical criteria.
The plan may consider:
- BMI
- Weight-related comorbidities
- Previous weight-management attempts
- Previous medications
- Participation in a reduced-calorie and physical-activity program
- Contraindications to preferred alternatives
- Age
- Diagnosis
- Continued response to treatment
- Percentage of weight lost during an initial approval period
All three questions must be evaluated separately.
| Question | What it determines | Possible result |
|---|---|---|
| Is W8MD in network? | Coverage for the medical visit | In-network, out-of-network, or self-pay visit |
| Is the GLP-1 medication covered? | Whether the pharmacy benefit includes the drug | Covered, nonpreferred, excluded, or not listed |
| Does the patient qualify? | Whether the insurer's medical criteria are satisfied | Approved, additional information requested, or denied |
GLP-1 medications that insurance may cover
Medications approved for chronic weight management
Insurance plans may cover one or more of the following:
- Wegovy injection — Semaglutide injection
- Wegovy pill — Oral Semaglutide
- Wegovy HD — Higher-dose Semaglutide injection for selected adults
- Zepbound — Tirzepatide injection
- Saxenda — Liraglutide injection
- Foundayo — Oral orforglipron
Plan formularies may prefer one product over another. A plan may require the patient to try a preferred medication before approving a nonpreferred medication.
Medications primarily approved for type 2 diabetes
Some GLP-1 and related medications are primarily approved for type 2 diabetes, including:
- Ozempic — Semaglutide
- Mounjaro — Tirzepatide
- Rybelsus — Oral Semaglutide for diabetes
- Trulicity — Dulaglutide
- Victoza — Liraglutide
- Byetta — Exenatide
- Bydureon — Extended-release Exenatide
A plan may require a documented diagnosis of type 2 diabetes before covering a diabetes-indicated medication. Obesity, prediabetes, or insulin resistance alone may not meet the plan's criteria for a diabetes product.
Wegovy and Ozempic both contain Semaglutide, but they have different FDA-approved indications. Zepbound and Mounjaro both contain Tirzepatide, but they also have different indications.
When W8MD can obtain prior authorization
W8MD can help obtain prior authorization when:
- The patient's plan includes coverage for the requested medication;
- The patient satisfies the insurer's BMI, diagnosis, and comorbidity criteria;
- The treatment is medically appropriate;
- The patient does not have a contraindication;
- The insurer permits the W8MD provider to submit an authorization request; and
- The required clinical documentation is available.
The process may include:
- Reviewing the patient's medical and weight history
- Calculating and documenting BMI
- Identifying qualifying comorbid conditions
- Reviewing previous diet, exercise, and medication attempts
- Selecting a medically appropriate covered medication
- Completing the plan's prior-authorization questions
- Providing office notes or other requested clinical records
- Submitting a medical-necessity statement when needed
- Responding to requests for additional information
- Reviewing approval, denial, or alternative-medication instructions
- Planning renewal documentation when continuing coverage
Prior authorization support does not guarantee approval. W8MD can prepare and submit documentation, but the insurance company makes the final coverage decision.
Prior authorization when W8MD is out of network
W8MD may still be able to help obtain authorization when it does not participate in the patient's medical insurance network.
This is often possible because prescription-drug benefits may be administered separately from medical-office benefits. A plan may accept a prescription and prior-authorization request from a licensed out-of-network provider even when the office visit itself is not processed as an in-network service.
Possible arrangements include:
- The patient uses out-of-network benefits for the W8MD visit while the medication is processed through the pharmacy benefit;
- The patient pays W8MD for the visit but uses insurance for the medication;
- The medical plan does not cover the visit, but the pharmacy plan accepts the prescription and authorization;
- The plan allows W8MD to submit prior authorization directly;
- The plan requires a plan-specific prescriber enrollment or authorization process;
- The plan requires the request to come from an in-network provider.
W8MD can often submit the request in most situations where the pharmacy benefit permits an out-of-network prescriber. However, some HMOs, Medicaid managed-care plans, closed-network plans, or employer plans may reject prescriptions or prior-authorizations from nonparticipating providers.
Patients should ask their plan:
- Can an out-of-network licensed provider prescribe a covered GLP-1 medication?
- Will the pharmacy benefit accept prior authorization from an out-of-network provider?
- Must the prescriber be enrolled with the plan?
- Does the medication require a referral from an in-network primary-care provider?
- Is an in-network obesity specialist required?
- Is an out-of-network office visit covered?
- Can the patient self-pay for the visit while using pharmacy insurance for the medication?
Important: Approval of the medication does not convert an out-of-network W8MD visit into an in-network visit. The patient may still be responsible for the visit cost, deductible, coinsurance, or balance permitted under the plan.
BMI and comorbidity requirements
Many plans use FDA weight-management eligibility standards as a starting point. Adult criteria commonly include:
- BMI of 30 kg/m² or higher; or
- BMI of 27 kg/m² or higher with at least one qualifying weight-related comorbid condition
However, insurers may impose stricter requirements. A plan may require a higher BMI, specific comorbidities, documented lifestyle treatment, or previous use of another medication.
Potential qualifying comorbidities may include:
- High blood pressure
- High cholesterol
- Type 2 diabetes
- Prediabetes
- Insulin resistance
- Obstructive sleep apnea
- Cardiovascular disease
- Coronary artery disease
- Osteoarthritis
- Metabolic dysfunction-associated steatotic liver disease
- Polycystic ovary syndrome
- Other obesity-related medical conditions recognized by the plan
BMI alone does not guarantee coverage
A patient may satisfy the FDA indication but still be denied because:
- The plan excludes obesity medication;
- The requested product is not on the formulary;
- The plan requires a different preferred medication;
- The patient has not completed step therapy;
- The plan requires documentation of a structured program;
- The plan uses stricter BMI criteria;
- The employer did not purchase weight-loss medication coverage.
Comorbidities alone may not guarantee coverage
A qualifying condition must usually be documented in the medical record. The insurer may request:
- Diagnostic history
- Laboratory results
- Blood-pressure readings
- Sleep-study results
- Medication history
- Relevant specialist records
- Evidence that the condition remains active
Information insurers commonly require
A GLP-1 prior-authorization request may require:
Patient information
- Full name
- Date of birth
- Insurance identification number
- Pharmacy-benefit information
- Current height and weight
- Current BMI
- Previous or baseline BMI
Medical information
- Obesity or overweight diagnosis
- Weight-related comorbidities
- Relevant laboratory results
- Blood-pressure history
- Sleep-apnea diagnosis or sleep-study results
- Diabetes status
- Cardiovascular history
- Liver and kidney considerations
- Contraindications
- Other prescribed medications
Previous weight-management efforts
The insurer may ask about:
- Nutrition changes
- Reduced-calorie diet
- Physical activity
- Behavioral treatment
- Commercial weight-loss programs
- Physician-supervised treatment
- Previous anti-obesity medications
- Duration and outcome of previous attempts
Medication-specific information
The plan may require:
- Requested medication
- Requested dose
- FDA-approved indication
- Reason a preferred medication is inappropriate
- Previous trial of a preferred drug
- Side effects or treatment failure
- Planned nutrition and activity support
Step therapy and formulary alternatives
Step therapy requires a patient to try one or more preferred treatments before the insurer will cover the requested medication.
For example, a plan may require:
- A trial of another weight-loss medication;
- Use of the plan's preferred GLP-1 product;
- Documented failure or intolerance of the preferred product;
- Participation in a structured lifestyle program; or
- Completion of a specific number of follow-up visits.
W8MD may recommend a different medication when it is medically appropriate and covered. However, a provider may request an exception when the preferred medication is contraindicated, previously ineffective, unavailable, or not clinically appropriate.
Reasons GLP-1 coverage may be denied
A denial does not always mean the medication is medically inappropriate. It may reflect the design of the insurance benefit.
Common denial reasons include:
Benefit exclusion
The policy does not cover medication used for weight management. An exclusion is usually more difficult to overturn than a missing-documentation denial because the employer or plan did not purchase the benefit.
Medication not on formulary
The requested drug is not included, or another product is preferred.
BMI criteria not met
The documented current or baseline BMI does not meet the plan's threshold.
No qualifying comorbidity
The plan requires at least one specific weight-related medical condition and does not recognize the documented condition.
Missing documentation
The insurer has not received the required weight, BMI, diagnosis, treatment history, or office notes.
Step therapy not completed
The patient has not tried the plan's preferred treatment.
Diabetes indication not met
The request involves Ozempic, Mounjaro, Rybelsus, or another diabetes medication, but the patient does not have type 2 diabetes or does not satisfy the plan's criteria.
Provider or network restriction
The plan requires an in-network or plan-enrolled prescriber.
Renewal criteria not met
The plan may require documentation of clinically meaningful weight loss, continued adherence, or ongoing participation in a weight-management program.
Duplicate therapy
The patient is already using another medication containing the same active ingredient or another GLP-1 medication.
What to do if additional information is requested
A request for additional information is not always a denial. The insurer may need:
- A current weight
- A baseline weight
- A corrected BMI
- Office notes
- A diagnosis code
- Proof of a comorbidity
- Previous medication dates
- Information about side effects
- Documentation of nutrition and activity efforts
- A preferred medication trial
- Confirmation that another GLP-1 medication was discontinued
Patients should respond promptly to W8MD requests for information. Delays in providing insurance cards, pharmacy-benefit details, previous records, or medication history may delay the decision.
Appealing a GLP-1 denial
Some denials can be appealed. The appropriate response depends on the denial reason.
An appeal may include:
- Corrected clinical information
- Updated weight and BMI
- Documentation of qualifying comorbidities
- Previous medication history
- Evidence of side effects or treatment failure
- A medical-necessity letter
- A formulary-exception request
- Evidence that step therapy is inappropriate
- Documentation of successful current treatment for a renewal denial
Patients generally have the right to ask an insurer to reconsider a coverage denial. Depending on the plan, the process may include an internal appeal followed by an external review.<ref name="HealthcareAppeal">How to appeal an insurance company decision(link). HealthCare.gov.Accessed 2026-07-22.</ref>
HealthCare.gov advises patients to keep copies of:
- The denial letter
- Explanation of benefits
- Prior-authorization submissions
- Appeal forms
- Medical-necessity letters
- Supporting medical records
- Correspondence with the insurer
A patient may also request an expedited review when a delay could seriously jeopardize health, although expedited-review criteria are controlled by the plan.
When an appeal may not succeed
An appeal may be unsuccessful when:
- Weight-loss medications are expressly excluded;
- The patient does not meet the plan's criteria;
- The medication is not a covered benefit;
- The requested use is considered investigational;
- The plan requires an in-network prescriber;
- Required step therapy has not been completed without a valid exception.
When an appeal is unlikely to succeed, W8MD can discuss covered alternatives and affordable self-pay pathways.
Insurance coverage for continued GLP-1 treatment
An initial approval does not necessarily provide indefinite coverage. Many plans authorize treatment for a limited period.
Renewal may require documentation of:
- Percentage of body weight lost
- Maintenance of previous weight loss
- Medication adherence
- Continued medical follow-up
- Participation in nutrition and activity changes
- Absence of serious adverse effects
- Continued medical necessity
- Current BMI or comorbid conditions
Patients should schedule follow-up visits before the authorization expires. Waiting until the last dose may cause a treatment interruption.
Insurance changes and continuity of treatment
A new calendar year, new employer, new pharmacy-benefit manager, or new plan may require:
- A new prior authorization
- A different preferred medication
- New step therapy
- A higher copay
- A new deductible
- Use of a different pharmacy
- Documentation from a new baseline
- A formulary-exception request
Previous approval by one plan does not bind a new plan.
Patients should retain:
- Previous approval letters
- Baseline and current weights
- Medication start dates
- Dose history
- Treatment response
- Previous side effects
- Records of previous medications
Medicare coverage
Medicare coverage for GLP-1 medications depends on the medication, indication, Part D plan, and current program rules.
As of July 2026, the Medicare GLP-1 Bridge program provides temporary nationwide access to certain qualifying beneficiaries with Medicare drug coverage. Covered products may include:
- Foundayo tablets
- Wegovy injection or tablets
- Zepbound KwikPen under program-specific rules
Eligibility, covered formulations, pharmacy requirements, and costs are controlled by Medicare and may change.<ref name="MedicareGLP1">Medicare coverage of weight-loss drugs(link). Medicare.gov.Accessed 2026-07-22.</ref>
Medicare may also cover certain medications for non-weight-loss FDA-approved indications, such as:
- Cardiovascular risk reduction in qualifying patients;
- Type 2 diabetes; or
- Moderate-to-severe obstructive sleep apnea in qualifying adults with obesity.
Patients should check their current Medicare drug plan and should not assume that every formulation or indication is covered.
Medicaid coverage
Medicaid coverage varies by state and managed-care plan. Requirements may include:
- State-specific eligibility criteria
- Specific BMI thresholds
- Qualifying comorbidities
- Use of preferred medication
- In-network prescriber enrollment
- Step therapy
- Documentation of a structured program
- Restrictions on particular formulations
Medicaid plans may be more likely than open commercial plans to require that the prescribing provider participate in or enroll with the plan. W8MD will evaluate whether submission is possible, but out-of-network authorization cannot be guaranteed.
Employer-sponsored coverage
Many commercial insurance policies are designed by the employer. Two patients with insurance cards from the same company may have very different benefits because their employers purchased different coverage.
An employer may:
- Cover anti-obesity medication;
- Cover only selected medications;
- Require a specific pharmacy-benefit program;
- Limit coverage to diabetes;
- Exclude weight-loss medications completely;
- Set a maximum annual benefit;
- Require enrollment in a separate weight-management program.
Patients may ask their human-resources or benefits department whether obesity medication is included in the plan.
Affordable options when insurance does not cover GLP-1 medication
If medication coverage is unavailable, W8MD may discuss:
- Budget Semaglutide-based options
- Budget Tirzepatide-based options
- Fully self-pay GLP-1 pathways
- Phentermine
- Phentermine/topiramate
- Qsymia
- Contrave
- Orlistat
- Diethylpropion
- Phendimetrazine
- Metformin
- Meal replacements
- Very low calorie diet programs
- Low-carbohydrate diet planning
- Behavioral and nutrition treatment
The most appropriate alternative depends on medical history, contraindications, current medications, blood pressure, cardiovascular risk, pregnancy potential, eating patterns, sleep, and treatment goals.
W8MD GLP-1 pricing
W8MD offers several insurance-supported and self-pay pathways.
| W8MD treatment pathway | Starting price | Notes |
|---|---|---|
| Semaglutide with insurance accepted for qualifying visits | From $29.99/week and up | Budget medication pathway for eligible patients. Starting price generally applies to an entry dose. |
| Tirzepatide with insurance accepted for qualifying visits | From $45/week and up | Budget medication pathway for eligible patients. Price generally increases with dose. |
| Self-pay Semaglutide | From $59.99/week and up | For eligible patients without visit coverage or those choosing a fully self-pay pathway. |
| Self-pay Tirzepatide | From $69.99/week and up | Subject to medical eligibility, dose, availability, and treatment plan. |
| Insurance-covered brand-name medication | Plan-specific copay, deductible, or coinsurance | May require prior authorization, step therapy, and use of an in-network pharmacy. |
Pricing disclaimer: Prices are starting prices and are not guaranteed for every medication, dose, or patient. Medication prices, visits, program fees, laboratory testing, pharmacy charges, copays, deductibles, and higher-dose costs may be separate.
A note about “generic” GLP-1 medications
Patients commonly search for:
- Generic Ozempic
- Generic Wegovy
- Generic Semaglutide
- Generic Mounjaro
- Generic Zepbound
- Generic Tirzepatide
However, a lower-cost or compounded product is not automatically an FDA-approved generic medication.
The FDA states that compounded GLP-1 drugs are not FDA-approved and are not the same as FDA-approved generic drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before marketing in the same way it reviews approved medications.<ref name="FDACompounded">FDA warns companies against illegal marketing of compounded GLP-1 medications(link). U.S. Food and Drug Administration.2026-03-03.Accessed 2026-07-22.</ref>
W8MD therefore uses more precise descriptions such as:
- Affordable Semaglutide-based option
- Affordable Tirzepatide-based option
- Budget GLP-1 pathway
- Self-pay GLP-1 option
The exact medication, formulation, source, regulatory status, price, and potential risks should be discussed during the medical evaluation.
What patients should ask their insurance company
Before the W8MD visit, call the member-services number on the insurance card and ask:
- Does my medical plan cover physician-supervised obesity or weight-management visits?
- Is W8MD or the individual provider in network?
- Do I have out-of-network benefits?
- Can I self-pay for the visit and still use my pharmacy benefit?
- Does my pharmacy plan cover anti-obesity medication?
- Are Wegovy, Zepbound, Foundayo, or Saxenda on the formulary?
- Which medication is preferred?
- Is prior authorization required?
- What BMI is required?
- Which comorbid conditions qualify?
- Is step therapy required?
- Is participation in a structured program required?
- Can an out-of-network provider submit the prior authorization?
- Must the prescriber enroll with the plan?
- Which pharmacy must dispense the medication?
- What are my copay, coinsurance, and deductible?
- What documentation is needed for renewal?
Record:
- The date and time of the call
- The representative's name
- The reference number
- The stated coverage criteria
- The required authorization form or portal
- The preferred pharmacy
A telephone representative's statement is not always a guarantee of payment, but it may help clarify the process.
What to bring to a W8MD insurance visit
Patients should bring or provide:
- Photo identification
- Medical insurance card
- Pharmacy-benefit card
- Medication list
- Allergy information
- Previous anti-obesity medication history
- Previous approval or denial letters
- Relevant laboratory results
- Sleep-study results if applicable
- Weight history
- Information about previous diet and exercise programs
- Name of the preferred pharmacy
- Any forms supplied by the insurance company
Accurate and complete information can reduce avoidable delays.
W8MD results and ongoing support
W8MD has provided physician-supervised medical weight-management care since 2011 and has helped thousands of patients work toward weight loss and long-term maintenance.
W8MD treatment may include:
- Insurance-supported medical visits
- GLP-1 prior authorization
- Medication selection
- Side-effect monitoring
- Nutrition counseling
- Protein planning
- Resistance training
- Sleep apnea screening
- Weight-loss plateau management
- GLP-1 maintenance therapy
- Prevention of weight regain
Results disclaimer: Individual results vary and are not guaranteed. Insurance approval does not guarantee weight loss, and a testimonial does not predict another patient's response.
Frequently asked questions
Does W8MD accept insurance for weight-loss visits?
W8MD accepts many insurance plans for qualifying medical weight-loss visits. Participation, covered services, referrals, copays, deductibles, and out-of-network benefits vary by plan.
Can W8MD obtain prior authorization for GLP-1 shots?
When the plan covers the medication and the patient meets the BMI, comorbidity, and other medical criteria, W8MD can document medical necessity and submit prior authorization. Approval is determined by the insurance company.
Can W8MD submit prior authorization if it is out of network?
In many cases, yes. W8MD can often submit a pharmacy prior authorization even when it does not participate in the patient's medical network, provided the pharmacy benefit accepts prescriptions and authorization requests from an out-of-network provider. Some plans require an in-network or enrolled prescriber.
Will an out-of-network W8MD visit be covered?
That depends on the medical plan. The patient may have out-of-network benefits, may need to meet an out-of-network deductible, or may need to self-pay. Medication coverage is a separate question.
Does insurance coverage of my visit mean Wegovy or Zepbound is covered?
No. Medical-visit coverage and pharmacy coverage are separate. A plan can cover the W8MD visit but exclude weight-loss medication.
What BMI is needed for insurance approval?
Many plans consider BMI of at least 30, or BMI of at least 27 with a qualifying comorbid condition. However, each insurer sets its own criteria and may require a higher BMI or additional documentation.
Which comorbidities may help a patient qualify?
Possible conditions include high blood pressure, high cholesterol, type 2 diabetes, prediabetes, sleep apnea, cardiovascular disease, osteoarthritis, and other obesity-related conditions recognized by the plan.
Can W8MD guarantee prior-authorization approval?
No. W8MD can prepare and submit clinical documentation, but the insurer controls approval.
What if weight-loss drugs are excluded from my plan?
W8MD can discuss affordable Semaglutide- and Tirzepatide-based options, self-pay pathways, traditional prescription weight-loss medications, nutrition treatment, and other alternatives.
How much is Semaglutide if insurance does not cover the medication?
When insurance is accepted for qualifying medical visits, W8MD Semaglutide-based options start from $29.99 per week and up. Fully self-pay Semaglutide starts from $59.99 per week and up.
How much is Tirzepatide if insurance does not cover the medication?
When insurance is accepted for qualifying medical visits, W8MD Tirzepatide-based options start from $45 per week and up. Fully self-pay Tirzepatide starts from $69.99 per week and up.
Can a denial be appealed?
Some denials can be appealed, particularly when information is missing, the patient's eligibility was misunderstood, or a formulary exception is medically justified. Benefit exclusions may be more difficult to overturn.
Does W8MD help with renewal prior authorizations?
W8MD may help with renewal documentation when the patient continues follow-up and meets the plan's continued-coverage criteria. Patients should schedule before the authorization expires.
Does insurance cover Ozempic for weight loss?
Many plans require type 2 diabetes for Ozempic coverage because Ozempic is not the Semaglutide brand specifically approved for chronic weight management. Wegovy is the Semaglutide product with a weight-management indication.
Does insurance cover Mounjaro for weight loss?
Many plans require type 2 diabetes for Mounjaro coverage. Zepbound contains Tirzepatide and is approved for chronic weight management and qualifying moderate-to-severe obstructive sleep apnea.
W8MD locations
Brooklyn and New York City
W8MD Weight Loss, Sleep and MedSpa
2632 East 21st Street, Suite L3
Brooklyn, New York 11235
Phone: (718) 946-5500
Serving patients from Brooklyn, Manhattan, Queens, Staten Island, the Bronx, Long Island, and nearby communities.
Philadelphia
W8MD Weight Loss, Sleep and MedSpa
1718 Welsh Road, 2nd Floor, Suite C
Philadelphia, Pennsylvania 19115
Phone: (215) 676-2334
Serving Northeast Philadelphia, Bucks County, Montgomery County, the Greater Philadelphia area, and nearby Pennsylvania communities.
Request a W8MD appointment
W8MD accepts many insurances for qualifying visits and can often submit GLP-1 prior authorization when medication coverage is available and the patient qualifies—even when W8MD is out of network, if the pharmacy benefit permits it.
Brooklyn: (718) 946-5500 • Philadelphia: (215) 676-2334
Related W8MD pages
Insurance and GLP-1 access
- GLP-1 prior authorization
- Insurance coverage for weight loss
- Affordable GLP-1 shots
- GLP-1 weight loss shots NYC
- GLP-1 shots Philadelphia
- GLP-1 weight loss injections
- Prescription weight loss medications
Semaglutide and Wegovy
- Semaglutide weight loss
- Semaglutide injection
- Wegovy for weight loss
- Wegovy pill
- Wegovy HD
- Ozempic for weight loss
- Semaglutide side effects
- Semaglutide dose escalation
- Semaglutide maintenance therapy
Tirzepatide and Zepbound
- Tirzepatide weight loss
- Tirzepatide injection
- Zepbound for weight loss
- Zepbound for sleep apnea
- Mounjaro for weight loss
- Tirzepatide side effects
- Tirzepatide dose escalation
- Tirzepatide maintenance therapy
Medical weight management
- Medical weight loss
- Physician-supervised weight loss
- W8MD weight loss doctors
- Nutrition counseling
- Meal replacements
- Weight loss maintenance
- Preventing weight regain
- Weight loss success stories
- Sleep apnea screening
References
<references />
External links
- HealthCare.gov prescription medication coverage
- Health-insurance appeals
- Medicare coverage for weight-loss drugs
- U.S. Food and Drug Administration drug information
- NIH BMI calculator
| GLP-1 receptor agonists, incretin therapy, and weight loss medications | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
